7 results match your criteria: "1Dana-Farber Cancer Institute[Affiliation]"

Prostate cancer survivors represent a growing population of patients with a diagnosis of prostate cancer, whether they were cured using local therapies or continue to receive systemic treatment of advanced disease. Many patients receive androgen deprivation therapy (ADT) during treatment, which is associated with many long-lasting physical and psychological effects. Identifying and addressing the needs of survivors is imperative for improving their health and well-being.

View Article and Find Full Text PDF

Purpose: Baseline use of corticosteroids is associated with poor outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition. To approach the question of causation versus correlation for this association, we examined outcomes in patients treated with immunotherapy depending on whether corticosteroids were administered for cancer-related palliative reasons or cancer-unrelated indications.

Patients And Methods: Clinical outcomes in patients with NSCLC treated with immunotherapy who received ≥ 10 mg prednisone were compared with outcomes in patients who received 0 to < 10 mg of prednisone.

View Article and Find Full Text PDF
Article Synopsis
  • The Adjuvant Paclitaxel and Trastuzumab trial investigated the effectiveness of a treatment regimen for small HER2-positive breast cancer, revealing a 7-year disease-free survival (DFS) rate of 93% and an overall survival (OS) rate of 95%.
  • The study involved 410 patients who received a specific combination of paclitaxel and trastuzumab for 12 weeks, followed by additional trastuzumab treatment, and analyzed factors related to cancer recurrence and patient health.
  • An exploratory analysis identified that 66% of the tumors were HER2-enriched, and a genetic factor was linked to an increased risk of paclitaxel-induced peripheral neuropathy (TIPN) in some patients
View Article and Find Full Text PDF

B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of the BCL-2 family of anti-apoptotic proteins that confers resistance to treatment with anti-cancer drugs; however, there are presently no agents that target BCL2A1. The MUC1-C oncoprotein is aberrantly expressed in triple-negative breast cancer (TNBC) cells, induces the epithelial-mesenchymal transition (EMT) and promotes anti-cancer drug resistance. The present study demonstrates that targeting MUC1-C genetically and pharmacologically in TNBC cells results in the downregulation of BCL2A1 expression.

View Article and Find Full Text PDF

Numerous instruments have been developed to measure pain within various populations; however, there remains limited understanding of how these tools are applicable to childhood cancer survivors. This study compared a single-item screening measure, the Pain Thermometer (PT), with a more in-depth measure, the Brief Pain Survey (BPS), in a cohort of childhood brain tumor survivors. Ninety-nine survivors (aged 13-32 years) with a median time from diagnosis of 9.

View Article and Find Full Text PDF

Background: Many U.S. adults have multiple behavioral risk factors, and effective, scalable interventions are needed to promote population-level health.

View Article and Find Full Text PDF